产品
编 号：F760001
分子式：C26H24N2O6S
分子量：492.54
分子式：C26H24N2O6S
分子量：492.54
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 736183-35-0
产品详情
生物活性：
BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache.
体内研究：
BGC-20-1531 free base (1-10 mg/kg; i.v.) causes a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow.Animal Model:Beagle dogs
Dosage:1-10 mg/kg
Administration:I.v.
Result:Caused a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow.
体外研究：
BGC-20-1531 free base competitively antagonized PGE2-induced vasodilatation of human middle cerebral (pKb=7.8) and meningeal (pKb=7.6) arteries, but had no effect on responses induced by PGE2 on coronary, pulmonary or renal arteries.
BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache.
体内研究：
BGC-20-1531 free base (1-10 mg/kg; i.v.) causes a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow.Animal Model:Beagle dogs
Dosage:1-10 mg/kg
Administration:I.v.
Result:Caused a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow.
体外研究：
BGC-20-1531 free base competitively antagonized PGE2-induced vasodilatation of human middle cerebral (pKb=7.8) and meningeal (pKb=7.6) arteries, but had no effect on responses induced by PGE2 on coronary, pulmonary or renal arteries.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备